Monte Rosa Therapeutics, Inc.
GLUE
$18.15
-$0.53-2.84%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -95.04% | -95.41% | 38.54% | 394.01% | 7,882.05% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -95.04% | -95.41% | 38.54% | 394.01% | 7,882.05% |
| Cost of Revenue | 38.90% | 8.52% | 35.79% | 13.16% | 20.85% |
| Gross Profit | -168.62% | -255.38% | -34.24% | 72.10% | 329.82% |
| SG&A Expenses | 15.19% | 15.83% | 8.48% | -16.85% | -2.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.65% | 10.19% | 27.98% | 3.78% | 13.56% |
| Operating Income | -213.62% | -482.31% | -24.31% | 52.35% | 226.01% |
| Income Before Tax | -193.18% | -395.34% | -27.20% | 63.08% | 249.62% |
| Income Tax Expenses | -93.67% | -97.27% | -4,574.65% | 375.79% | 890.36% |
| Earnings from Continuing Operations | -194.92% | -443.34% | -13.50% | 59.44% | 246.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -194.92% | -443.34% | -13.50% | 59.44% | 246.66% |
| EBIT | -213.62% | -482.31% | -24.31% | 52.35% | 226.01% |
| EBITDA | -204.17% | -416.14% | -26.43% | 56.09% | 239.44% |
| EPS Basic | -178.06% | -429.65% | -12.99% | 64.84% | 207.40% |
| Normalized Basic EPS | -176.72% | -383.57% | -26.59% | 67.99% | 209.42% |
| EPS Diluted | -178.95% | -430.05% | -13.44% | 65.12% | 207.26% |
| Normalized Diluted EPS | -177.47% | -383.57% | -26.59% | 67.99% | 208.36% |
| Average Basic Shares Outstanding | 21.59% | 4.18% | 0.47% | 15.38% | 36.56% |
| Average Diluted Shares Outstanding | 20.41% | 4.18% | 0.47% | 15.38% | 37.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |